| 期刊論文1. | Lang, H. C.、Su, T. P.(2004)。The cost of schizophrenia treatment in Taiwan。Psychiatric Services,55(8),928-930。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 2. | Lieberman, J. A.、Stroup, T. S.、McEvoy, J. P.、Swartz, M. S.、Rosenheck, R. A.、Perkins, D. O.、Hsiao, J. K.(2005)。Effectiveness of antipsychotic drugs in patients with chronic schizophrenia。New England Journal of Medicine,353(12),1209-1223。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 3. | Russell, Louise B.、Gold, Marthe R.、Siegel, Joanna E.、Daniels, Norman、Weinstein, Milton C.(1996)。The Role of Cost-Effectiveness Analysis in Health and Medicine。JAMA,276(14),1172-1177。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 4. | Lee IH, Chen PS, Yang YK, et al,(2008)。The functionality and economic costs of outpatients with schizophrenia in Taiwan。Psychiatry Res,158,306-15。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 5. | Lieberman JA(1996)。Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis。J Clin Psychiatry,57,68S-71S。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 6. | Kane J, Canas F, Kramer M, et al.(2007)。Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial。Schizophr Res,90,147-61。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 7. | Tzimos A, Samokhvalov V, Kramer M, et al.(2008)。Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension。Am J Geriatr Psychiatry,16,31-43。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 8. | Wang Q, Wang J, Sun LJ, et al.(2009)。Salidroside protects the hypothalamic-pituitary-gonad axis of male rats undergoing negative psychological stress in experimental navigation and intensive exercise。Zhonghua Nan Ke Xue,15,331-6。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 9. | Davidson M, Emsley R, Kramer M, et al.(2007)。Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study。Schizophr Res,93,117-30。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 10. | Marder SR, Kramer M, Ford L, et al.(2007)。Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study。Biol Psychiatry,62,1363-70。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 11. | Potkin SG, Gharabawi GM, Greenspan AJ, et al(2006)。A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization。Schizophr Res,85,254-65。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 12. | Arvanitis LA, Miller BG(1997)。Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group。Biol Psychiatry,42,233-46。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 13. | Citrome L, Jaffe A, Levine J, Lindenmayer J-P(2005)。Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies.。J Clin Psychiatry,66,1512-6。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 14. | Cramer J, Rosenheck R, Xu W, Henderson W, Thomas J, Charney D(2001)。Detecting improvement in quality of life and symptomatology in schizophrenia。Schizophr Bull,27,227-36。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 15. | Beasley CM, Jr., Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S(1996)。Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial.。Psychopharmacology (Berl),124,159-67。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 16. | Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S(1996)。Olanzapine versus placebo and haloperidol acute phase results of the north American double-blind olanzapine trial。Neuropsychopharmacology,14,111-23。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 17. | Fabre LF, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB(1995)。ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia。Clin Ther,17,366-78。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 18. | Borison R, Arvanitis L, Miller B(1996)。ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia。J Clin Psychopharmacol,16,158-69。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 19. | Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG(1997)。Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Seroquel Study Group。Archives of General Psychiatry,54,549-57。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 20. | Dossenbach M, Arango-Davila C, Silva Ibarra H, et al.(2005)。Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study。J Clin Psychiatry,66,1021-30。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 21. | Menzin J, Boulanger L, Friedman M, Mackell J, Lloyd JR。Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program。Psychiatr Serv,54,719-23。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 22. | Su ZY, Wang YT(2009)。A molecular dynamics simulation of the human lysozyme: Camelid VHH HL6 antibody system。Int J Mol Sci,10,1719-27。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 23. | Li ZD, Hu XW, Wang YT, Fang J(2009)。Apigenin inhibits proliferation of ovarian cancer A2780 cells through Id1。FEBS Lett,583,1999-2003。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 24. | Siegel JE, Weinstein MC, Russell LB, Gold MR(1996)。Recommendations for reporting cost-effectiveness analyses: Panel on Cost-Effectiveness in Health and Medicine。JAMA,276,1339-41。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 25. | Launois R, Schulenburg MGvd, Knapp M, Toumi M(1998)。Cost-effectiveness of sertindole versus olanzapine or haloperidol: a comprehensive model。Int J Psychiat Clin Pract,2,79S-86S。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | 26. | Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB(1996)。Recommendations of the panel on cost-effectiveness in health and medicine。JAMA,276,1253-8。 ![](/gs32/thssjcncl/image/nclsfx.gif) ![new window](/gs32/images/newin.png) | |
| |